Company Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.
It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage.
NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | John Trainer M.B.A. |
Contact Details
Address: 9119 Gaither Road Gaithersburg, Maryland United States | |
| Website | https://www.neximmune.com |
Stock Details
| Ticker Symbol | NEXI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001538210 |
| CUSIP Number | 65344D109 |
| ISIN Number | US65344D2080 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chad Rubin | Senior Vice President of Corporate Affairs |
| Craig R. Jalbert CIRA | President, Treasurer, CS, Principal Executive Officer, Financial Off, & Principal Accounting Off |
| Dr. Daniel P. Bednarik | Senior Vice President of Molecular Engineering & Protein Design |
| Dr. Jack A. Ragheb M.D., Ph.D. | Senior Vice President of Translational Science |
| Dr. Robert Douglas Knight M.D. | Chief Medical Officer |
| John Trainer M.B.A. | Consultant |
| Karen Haslbeck | Head of Human Resources |
| Matthew Schiller | Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 06, 2024 | 25-NSE | Filing |
| Aug 27, 2024 | S-8 POS | Filing |
| Aug 27, 2024 | S-8 POS | Filing |
| Aug 27, 2024 | S-8 POS | Filing |
| Aug 27, 2024 | POS AM | Filing |
| Aug 27, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |
| Aug 07, 2024 | 10-Q | Quarterly Report |
| Aug 02, 2024 | DEFA14A | Filing |
| Aug 02, 2024 | 8-K | Current Report |